Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of AK3280 in healthy Chinese volunteers
NCT04926116Phase 1Completed
- Sponsor
- Ark Biosciences
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AK3280 in idiopathic pulmonary fibrosis (IPF), sponsored by Ark Biosciences. Primary endpoint: Percentage of Subjects with Adverse Events (AEs) at 6 weeks. Started Jun 2021; status: completed.
02
Drugs
AK3280
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04926116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926116.